Sean Parker's cancer-fighting institute aims 1st trial at tough target
Small Peninsula biotech company Apexigen and drug giant Bristol-Myers Squibb are teaming with the Parker Institute for Cancer Immunotherapy in an early-stage trial in metastatic pancreatic cancer patients.
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Ron Leuty Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Health Management | Immunotherapy | Pancreas | Pancreatic Cancer